Clinical study of multi-mode long-acting analgesia after hemorrhoid surgery based on ERAS concept

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053343

Enrollment

Unknown

Registered

2021-11-19

Start date

2021-11-11

Completion date

Unknown

Last updated

2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoids

Interventions

Multi-mode long-acting analgesia group A:The wound surface was coated with methylene blue and infiltrated with ropivacaine + point injection of ropivacaine + intravenous injection of paraccoxib sodium

Multi-mode long-acting analgesia group B:The wound surface was coated with methylene blue + point injection of ropivacaine + intravenous injection of paraccoxib sodium

Multi-mode analgesia group C:The wound surface was infiltrated with ropivacaine + point injection of ropivacaine + intravenous injection of paraccoxib sodium

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with grade III~IV internal hemorrhoids and mixed hemorrhoids with prolapse who are suitable for surgery meet the diagnostic criteria of hemorrhoids in the Guidelines for the Diagnosis and Treatment of Hemorrhoids in China (2020); 2. Aged 18-75 years, and the course of disease ranged from 3 months to 10 years; 3. Clear consciousness, able to cooperate with clinical data collection; 4. The function of vital organs of the whole body is normal; 5. Voluntarily join the experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with other rectoanal and intestinal diseases, such as perianal abscess, rectal polyps, rectal tumors, inflammatory bowel disease, etc.; 2. History of hemorrhoids surgery, abnormal anal morphology and function; 3. Patients with severe anemia, malignant tumor, uremia and other systemic diseases, and history of mental diseases such as depression; 4. Used analgesics within 48 hours before surgery or antidepressants 1 week before surgery; 5. Patients who have a history of allergy to the drugs involved in this study; 6. Pregnant and lactating women; 7. Those who have adverse events and are not suitable to continue to participate in the study; 8. Patients who cannot be treated according to the requirements of this study and whose data are incomplete; 9. Patients who are participating in clinical trials of other drugs.

Design outcomes

Primary

Measure	Time frame
VAS(Visual Analogue Scale) pain grade;BCS(Bruggrmann comfort scale);	—

Countries

China

Contacts

Public ContactGu Yunfei

Affiliated Hospital of Nanjing University of Chinese Medicine

646073793@qq.com+86 13615230723

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026